



Oncology & PK Services for Drug Development

We support the design and execution of preclinical oncology studies, delivering comprehensive pharmacokinetic insights from tumor model selection to bioanalytical readout. Together, we develop study designs tailored to your test compound and research question, combining advanced tumor modeling with high-sensitivity in vivo imaging, cell-based assays, and precise molecular quantification. This supports the characterization, efficacy testing, and PK-profiling of your therapeutic candidates.

All assays are developed and validated according to study-specific requirements and high animal welfare standards.

Services	Description
<i>in vivo</i> Tumor Modeling	Syngeneic, orthotopic, and CDX modeling tailored to immunocompetent, immunodeficient, or humanized hosts
<i>in vivo</i> Tumor Imaging	Longitudinal monitoring of tumor progression and therapy response in mice and rats using specialized luminescent tumor models
Cell-based Assays & Molecular Analyses	Tumor cell proliferation and drug cytotoxicity, IC50 determination, apoptosis assays; ELISA, ECLIA, ddPCR and automated Western blot (Jess)
Pharmacokinetics (PK)	Precise quantification of test compound concentration, specializing in human antibody detection in animal models
Circulating DNA (ctDNA)	Ultra-sensitive detection and absolute quantification of tumor-specific circulating DNA using ddPCR technology
Tumor-PK Integration	Integrated analysis of imaging data and molecular biomarkers to evaluate the efficacy of oncology drug candidates in rodent models